|
⚲
|
| Keyboard |
| Stempoint Capital LP
✚
|
|
|---|---|
| CRD # | 324248 |
| SEC # | 801-127041 |
| CIK # | 0001952142 |
| AUM | 761.3 M (2026-03-30) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-540-4099 |
| Address | 520 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Thu, 30 Jul 2026 | Stempoint Capital LP Takes $1.23 Million Position in LB Pharmaceuticals Inc $LBRX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Has $34.94 Million Stock Position in Abivax SA Sponsored ADR $ABVX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Acquires New Holdings in Biodesix, Inc. $BDSX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Makes New $4.89 Million Investment in Nurix Therapeutics, Inc. $NRIX — MarketBeat |
| Thu, 30 Jul 2026 | Stempoint Capital LP Buys 125,581 Shares of Evommune, Inc. $EVMN — MarketBeat |
| CIK | Period |
|---|---|
| 0001952142 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Scholar Rock Holding Corp | 111.6 | ||
| Revolution Medicines Inc | 74.2 | ||
| Abivax Sa | 69.9 | ||
| Syndax Pharmaceuticals Inc | 63.8 | ||
| Health Sciences Acquisitions Corp | 42.1 | ||
| Praxis Precision Medicines Inc | 36.3 | ||
| Boston Scientific Corp | 31.4 | ||
| MBX Biosciences Inc | 29.8 | ||
| Mineralys Therapeutics Inc | 28.9 | ||
| Imara Inc | 28.5 | ||
| CG Oncology Inc | 27.8 | ||
| Biohaven Ltd | 27.0 | ||
| TYRA Biosciences Inc | 22.5 | ||
| Roivant Sciences Ltd | 21.4 | ||
| Psivida Corp | 20.9 | ||
| Arcutis Biotherapeutics Inc | 19.5 | ||
| Structure Therapeutics Inc | 19.3 | ||
| Consonance-HFW Acquisition Corp | 19.2 | ||
| Amylyx Pharmaceuticals Inc | 18.6 | ||
| Dyne Therapeutics Inc | 18.4 | ||
| Edgewise Therapeutics Inc | 18.3 | ||
| Cytokinetics Inc | 17.1 | ||
| Aeglea Biotherapeutics Inc | 16.9 | ||
| Denali Therapeutics Inc | 16.4 | ||
| Xenon Pharmaceuticals Inc | 16.4 | ||
| Celldex Therapeutics Inc | 16.1 | ||
| Protagonist Therapeutics Inc | 15.3 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Stempoint Capital Opportunity Master Fund LP | [2025-03-28] | 75.7 M | 137.0 M |
| Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Stempoint Capital Master Fund LP | [2023-02-02] | 72.4 M | 447.4 M |
| Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 645.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 116.3 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 761.3 |
| By Discretionary | ||
| Discretionary | 8 | 761.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 761.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 645.0 | |
| United States Persons | 116.3 | |
| Total | 8 | 761.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Robert Duggan | Director | 29 | 7 | |
| Miles Perryman | Director | 8 | 4 | |
| Sean Tan | Director | 9 | 2 | |
| Stempoint Capital LP | Promoter | 4 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001952142] | |
| SC 13G | [0001952142] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Stempoint Capital LP | Sensei Biotherapeutics Inc | [2026-05-15] |
| Stempoint Capital LP | Xilio Therapeutics Inc | [2025-11-14] |
| Stempoint Capital LP | Surrozen Inc/DE | [2024-11-01] |
| Stempoint Capital LP | Vistagen Therapeutics Inc | [2024-02-12] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300SQHSDQCTFLCL20 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Benchmark Plus Management LLC
✚
|
WA | 767.4 M |
|
Coinfund Management LLC
✚
|
NY | 766.0 M |
|
Orange Investment Advisors LLC
✚
|
FL | 765.0 M |
|
Lepercq de Neuflize Asset Management LLC
✚
|
NY | 763.7 M |
|
Stonecastle Advisors LLC
✚
|
NY | 763.4 M |
|
Sciencast Management LP
✚
|
NJ | 760.0 M |
|
Shrewsbury River Capital LP
✚
|
NJ | 757.5 M |
|
Riva Ridge Capital Management LP
✚
|
NY | 757.5 M |
|
Mill Hill Capital LLC
✚
|
NY | 757.2 M |
|
Alight Capital Management LP
✚
|
NY | 754.4 M |